TLPH · Talphera, Inc.
$1.19
+0.00 (+0.00%)
At close · Aug 21
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring.”View the 10-Q filed Aug 12, 2026
Market Cap
$61.77M
Shares
51.91M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,117,277 |
| Vincent J. Angotti | Chief Executive Officer | $1,117,277 |
| Raffi Asadorian | Chief Financial Officer | $727,309 |
| Shakil Aslam | Chief Medical Officer | $654,840 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $1,038,992 |
| Vincent Angotti | CEO | $1,038,992 |
| Raffi Asadorian | Chief Financial Officer | $709,857 |
| Badri Dasu | Chief Engineering Officer | $575,959 |
| Shakil Aslam | Chief Medical Officer | $529,242 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $1,211,994 |
| Vincent Angotti | CEO | $1,211,994 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $814,270 |
| Raffi Asadorian | Chief Financial Officer | $742,609 |
| Badri Dasu | Chief Engineering Officer | $602,166 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,297,016 |
| Vincent J. Angotti | Chief Executive Officer | $1,297,016 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $822,400 |
| Raffi Asadorian | Chief Financial Officer | $755,144 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $2,447,954 |
| Vincent Angotti | CEO | $2,447,954 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,507 |
| Raffi Asadorian | Chief Financial Officer | $1,024,610 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $1,765,522 |
| Vincent Angotti | CEO | $1,765,522 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $962,122 |
| Raffi Asadorian | Chief Financial Officer | $890,716 |
| Badri Dasu | Chief Engineering Officer | $686,353 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $2,125,052 |
| Vincent J. Angotti | Chief Executive Officer | $2,125,052 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,333 |
| Raffi Asadorian | Chief Financial Officer | $1,013,492 |
| Badri Dasu | Chief Engineering Officer | $776,258 |
| Lawrence G. Hamel | — | $776,018 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,738,845 |
| Vincent J. Angotti | Chief Executive Officer | $1,738,845 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,063,956 |
| Raffi Asadorian | Chief Financial Officer | $907,235 |
| Badri Dasu | Chief Engineering Officer | $734,208 |
| Former Chief Development | Officer | $688,617 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $2,353,923 |
| Vincent Angotti | CEO | $2,353,923 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $874,093 |
| Raffi Asadorian | Chief Financial Officer | $606,287 |
| Badri Dasu | Chief Engineering Officer | $595,179 |
| Former Chief Development | Officer | $595,179 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Wan | Class III director | Appointed | 2026-06-23 |
| Joseph Todisco | Class III director | Appointed | 2026-06-23 |
| Marina Bozilenko | Class III director | Appointed | 2026-06-23 |
| Abhinav Jain | Class II director | Appointed | 2025-10-24 |
| Stephen J. Hoffman | Class II director | Appointed | 2025-10-24 |
| Vincent J. Angotti | Class II director | Appointed | 2025-10-24 |
| Joseph Todisco | Class III member of the board of directors and member of the compensation committee | Appointed | 2025-10-16 |
| Pamela P. Palmer, MD, PhD | Chief Medical Officer | Resigned | 2024-08-14 |
| Jill Broadfoot | Class I director | Appointed | 2024-06-24 |
| Adrian Adams | Class I director | Appointed | 2024-06-24 |
| Pamela P. Palmer, M.D., Ph.D. | member of the Company's board of directors | Resigned | 2024-03-01 |
| Howard B. Rosen | member of the board of directors | Resigned | 2024-03-01 |
| Richard Afable, M.D. | member of the board of directors | Resigned | 2024-03-01 |
| Abhinav Jain | Class II Director | Appointed | 2024-01-22 |
| Mark Wan | Class III director | Appointed | 2023-10-10 |
| Howard B. Rosen | Class III director | Appointed | 2023-10-10 |
| Marina Bozilenko | Class III director | Appointed | 2023-10-10 |
| Mark G. Edwards | member of the board of directors | Resigned | 2022-03-01 |
| Jill M. Broadfoot | Class I director | Appointed | 2021-11-23 |
| Mark G. Edwards | Class I directors | Appointed | 2021-06-17 |
| Richard Afable, M.D. | Class I directors | Appointed | 2021-06-17 |
| Adrian Adams | Class I directors | Appointed | 2021-06-17 |
| Marina Bozilenko | Class III director | Appointed | 2021-03-31 |
| Mark Wan | Class III director | Appointed | 2020-06-16 |
| Howard B. Rosen | Class III director | Appointed | 2020-06-16 |
Key facts
CIK
1427925
CUSIP
00444T209
13F (30d)
50 filings
49 filers
Visit website
Investor relations